Melitracen

N, N- dimethyl-3- (10,10 - dimethyl- 9 ,10- dihydroanthracene -9 -ylidene) propylamine

  • C21H25N
  • C21H25N · HCl (hydrochloride)
  • 5118-29-6 ( Melitracen )
  • 10563-70-9 ( Melitracen · hydrochloride)
  • N06AA14
  • N06CA02

Antidepressant

  • 291.43 g · mol -1
  • 327,90 g.mol -1 (hydrochloride)

245-248 ° C ( Melitracen · hydrochloride)

Template: Infobox chemical / molecular formula search available

Melitracen is a tricyclic antidepressant with the characteristic for this group of pharmacological properties. In particular, to amitriptyline it shows a great similarity. In doses of less than 150 mg, it is non-sedative.

Melitracen was patented in 1963 by Kefalas A / S and is used in Europe, together with the neuroleptic flupentixol as a combined preparation in drug Deanxit ®. In Germany no drugs with the drug Melitracen are commercially available.

Application

Mild to moderate depressive states self-consciousness and anxiety. Deanxit ® (10 mg and 0.5 mg flupentixol Melitracen ) affects mood enhancing and anxiolytic. It is used to treat mild to moderate depression, which are characterized by anxiety, loss of the ability to be happy, fruitless brooding, fear of failure and guilt. Also, trigeminal neuralgia, neurosis and aphthous ulcers are treatable in combination with flupentixol.

Side effects

Possible side effects include drowsiness, nausea, constipation, headache.

Production

Melitracen is synthesized from anthrone in several stages.

CAS registry number Anatomical Therapeutic Chemical Classification System Active ingredient
224079
de